As of November 6, 2026, Medpace Holdings, Inc. is a publicly traded company (Nasdaq: MEDP). The largest holder reporting an active stake on Schedule 13D is August J. Troendle, the chief executive and president, at 19.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include T. Rowe Price (7.2%) (Schedule 13D/A, September 28, 2026).
Is this your company?
About to sign with, pay or invest in Medpace Holdings, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Medpace Holdings, Inc. a real, registered company?
- Medpace Holdings, Inc. files with the SEC under CIK 1668397 (its SEC filings).
- Its shares are listed under the ticker MEDP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cincinnati, Ohio, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Medpace Holdings, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Brad W. Hansman, Executive Vice President, Operations (Form 8-K filed 2026-06-04). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names August J. Troendle (filed 2026-09-28).
Who are Medpace Holdings, Inc.'s owners and officers?
Medpace Holdings, Inc.: incorporated in Delaware; business address in Cincinnati, Ohio; industry Services-Commercial Physical & Biological Research (Schedule 13D/A, 2026-09-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-09-28 | August J. Troendle | 19.1% |
| Schedule 13G, 2026-08-14 | T. Rowe Price Associates, Inc. | 7.2% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13D/A, 2025-12-01 | August J. Troendle | 20% |
Questions about who owns Medpace Holdings, Inc.
Who owns Medpace Holdings, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Medpace Holdings, Inc.: August J. Troendle (19.1%, Schedule 13D/A, filed 2026-09-28) and T. Rowe Price Associates, Inc. (7.2%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Medpace Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Medpace Holdings, Inc. on this page are August J. Troendle (19.1%) and T. Rowe Price Associates, Inc. (7.2%).
When did August J. Troendle buy into Medpace Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from August J. Troendle on this page is the Schedule 13D/A, filed 2025-12-01, reporting 20%; its latest, Schedule 13D/A filed 2026-09-28, reports 19.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Medpace Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Medpace Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Medpace Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-04 | Brad W. Hansman | Executive Vice President, Operations | appointed | 2026-06-01 |
| Form 8-K, 2026-04-22 | Jesse Geiger | President | departed | 2026-05-31 |
Which insiders own Medpace Holdings, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 5,071,244 shares (18.1% of shares outstanding), 338,225 held directly and 4,733,019 indirectly (Form 4, 2026-10-01).
- , the executive vice president and operations: 54,012 shares (0.19% of shares outstanding) (Form 4, 2026-10-28).
- , a director: 27,861 shares (0.10% of shares outstanding) (Form 4, 2026-10-02).
- , the general counsel and amp: 19,098 shares (0.07% of shares outstanding) (Form 4, 2026-11-02).
- , the president: 15,000 shares (0.05% of shares outstanding) (Form 4, 2026-03-19).
Shares outstanding: 27,971,686 as of 2026-10-16, from the company's latest SEC cover page.
How much has Medpace Holdings, Inc. raised?
No fundraising or offering filing from Medpace Holdings, Inc. is on file with us.
Keep reading
More on Medpace Holdings, Inc. and the records around it.
Medpace Holdings, Inc. elsewhere on the record
- Leadership changes Jun 2026
Companies that share a holder
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/medpace